Loading
NASDAQHealthcareMedical - Devices
Latest quote
$0.1466
−$0.0029 · -1.94%
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Regular session
$0.1466
−$0.0029 · -1.94%
Regular session · ET · Market data may be delayed.
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Day range
Current $0.1466
52-week range
Current $0.1466
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
67
Undervalued
Sentiment
59
Mixed
Risk
96
Extreme Risk
Momentum
17
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Vivos Therapeutics, Inc. operates as a medical technology company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.
Day range
Current $0.1466
52-week range
Current $0.1466
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 17.44M USD | 15.03M USD | 13.8M USD | 16.02M USD | 16.89M USD |
| Cost of goods sold | 6.9M USD | 6.01M USD | 5.53M USD | 6.01M USD | 4.28M USD |
| Gross profit | 10.54M USD | 9.02M USD | 8.27M USD | 10.02M USD | 12.6M USD |
| Selling, general, and administrative | 29.13M USD | 19.61M USD | 24.95M USD | 34.38M USD | 31.34M USD |
| Operating expenses | 30.44M USD | 20.19M USD | 25.57M USD | 35.05M USD | 32.08M USD |
| Interest income | — | — | — | 89K USD | 117K USD |
| Interest expense | — | — | — | — | 14K USD |
| Depreciation and amortization | 1.31M USD | 581K USD | 621K USD | 669K USD | 733K USD |
| Operating income | −19.89M USD | −11.17M USD | −17.3M USD | −25.03M USD | −19.47M USD |
| Net income | −21.23M USD | −11.14M USD | −13.58M USD | −23.85M USD | −20.29M USD |
Company facts updated Oct 9, 2026.
Reported history and fiscal-year consensus
Reported history and fiscal-year consensus
Funds reporting this stock among their holdings, ordered by reported position size.
AI-generated and delayed market data for informational and educational purposes only. Not investment advice.
